LinkedIn
WebsiteIntroduction
Universe Pharmaceuticals Inc (NASDAQ: UPC) is a pharmaceutical producer and distributor headquartered in Jiâan, Jiangxi, China. Established in 2013, the company operates in two primary areas: manufacturing and marketing traditional Chinese medicine derivatives across 30 provinces in China, and advancing early-stage biologics and drug delivery innovations.
Corporate Structure and Experience
According to its LinkedIn profile, Universe Pharmaceuticals employs between 11 and 50 people, a size that supports agile decision-making and focused research initiatives. Senior management includes a CEO, CFO, and a board of directors re-elected at the Annual General Meeting held September 2â3, 2025. Shareholders approved all four director elections with between 89.62% and 94.23% of votes cast, although total participation was recorded at 2.55%.
Pharmaceuticals by freestocks
Recent Developments and News
- On March 20, 2025, the company announced a one-for-forty share consolidation, effective March 24, 2025. Pre-consolidation shares with a par value of US$0.28125 each combined into one share with a par value of US$11.25. The ticker remains âUPC,â but now under a new CUSIP number.
- The Annual General Meeting originally scheduled for August 26, 2025, was adjourned due to a lack of quorum and reconvened on September 2, concluding on September 3, 2025, with all governance proposals adopted.
- As of now, there are no announced dividends, and no recent news releases beyond the share consolidation and meeting notices.
Financial and Strategic Analysis
As of December 26, 2025, UPC shares closed at US$6.6279, reflecting an increase of 54.68% on volume of 493,867. Key trailing-twelve-month metrics include:
| Metric | Value |
|---|---|
| Revenue | US$19.29 M |
| Net Margin | 5.65% |
| Gross Margin | 30.41% |
| EPS (TTM) | US$8,030.58 |
| EBITDA (TTM) | -US$8.10 M |
| Debt/Equity (MRQ) | 14.01% |
| Beta (5Y) | 1.52 |
Market capitalization is approximately US$3.75 million with 563,300 shares outstanding. Average daily volume over the past ten days is 20,000 shares, suggesting ongoing liquidity challenges that the share consolidation may address by meeting minimum bid price requirements on Nasdaq.
The consolidation may refine the equity structure and attract institutional interest. Continued board re-elections suggest governance stability; however, low shareholder turnout indicates potential areas for improved investor engagement.
Market Position and Industry Context
Universe Pharmaceuticals operates in two segments. In China, it provides traditional medicine derivatives, biomedical drugs, medical instruments, and dietary supplements, aligning with the nationâs aging demographic and rising healthcare needs. On the global biotechnology front, the company utilizes early-stage research partnerships and precision manufacturing, situating it among small to mid-size biotechs that explore novel drug delivery systems. A beta above 1.0 indicates stock sensitivity to market fluctuations, which is characteristic of companies managing emerging-market operations alongside research and development.
tl;dr
On March 24, 2025, Universe Pharmaceuticals completed a 40-for-1 share consolidation, merging forty US$0.28125 shares into one US$11.25 share under the same ticker (UPC). Following this development, the stock price increased to US$6.63 (+54.68%); however, average daily volume remains modest. Governance was reaffirmed at the September 2025 Annual General Meeting despite low shareholder turnout. Market analysts will monitor whether the consolidated share structure and enhanced communications will improve liquidity and support the companyâs dual focus on Traditional Chinese Medicine distribution and biotech research.
